Taking a mental health leave from work is an option most people don't know about
NEW YORK (AP) — Her first panic attack came at a company-wide meeting, right before her scheduled presentation. Carolina Lasso had given many similar talks about her marketing team's accomplishments. When her name was called this time, she couldn't speak.
'I felt a knot in my throat,' Lasso said. 'My head, it felt like it was inside a bubble. I couldn't hear, I couldn't see, and it felt like an eternity. It was just a few seconds, but it was so profound, and in a way earth-shattering to me.'
Lasso was struggling after a cross-country move followed by a divorce. Her boss suggested a mental health leave, a possibility she didn't know existed. She worried whether taking time off would affect how her team viewed her or cost her a future promotion, but in the end she did.
'I'm thankful for that opportunity to take the time to heal," Lasso, 43, said. 'Many people feel guilty when they take a leave of absence when it's mental health-related. ... There is some extra weight that we carry on our shoulders, as if it had been our fault.'
Despite a fear of repercussions, more adults are recognizing that stepping back from work to deal with emotional burdens or psychological conditions that get in the way of their lives is a necessary choice, one that a growing number of employers recognize.
ComPsych Corp., a provider of employee mental health programs and absence management services, encourages its business clients to make the well-being of workers a priority before individuals get to a breaking point while also having processes in place for those who require leaves of absence.
'Since the start of the COVID-19 pandemic, collectively we've just been in this constant state of turmoil,' Jennifer Birdsall, the senior clinical director at ComPysch, said. 'We just have had this barrage of change and uncertainty.'
Depression, anxiety and adjustment disorder, which involves excessive reactions to stress, were the top three diagnoses of employees who took mental health leaves in the past two years among clients of Alight, a Chicago-based technology company which administers leaves and benefits for large employers.
Structuring a leave
A mental health leave can last weeks or months. In some cases, workers get approval to work a reduced schedule or to take short periods of time off when needed, using an approach called 'intermittent leave.'
At most U.S. organizations with 50 or more employees, people can request leaves through the Family and Medical Leave Act. The federal law entitles workers with serious health conditions to paid or unpaid leaves of up to 12 weeks, depending on state and local laws.
Some employers require people to use sick days or accumulated vacation days to continue receiving a paycheck while out. For longer leaves, workers can access short-term disability plans, if their employer offers one.
Lasso's leave lasted six months, and included therapy and travel to India for additional treatment. She returned to her job but decided after a year to leave for good. She later launched a business to train people on fostering a more humane work culture.
A mental health leave is 'not only OK, but it can really unlock new possibilities once we have the time to do the work — therapy, medication, whatever it is — and have enough distance from work to be able to reconnect with ourselves,' Lasso said.
Talking openly about struggles
A social stigma around mental health challenges causes many people to avoid seeking treatment or requesting a leave of absence. Newton Cheng, director of health and performance at Google, hopes to change that by sharing his own struggles.
His first self-disclosure happened during the pandemic, when a senior manager invited employees at a meeting to share how they were doing. When it was his turn, Cheng started crying.
He explained he was struggling to live up to his expectations of himself as a father and didn't know how to turn things around.
'It was just totally horrifying to me because, one, I had just cried in front of my coworkers and I was definitely taught as a professional — and as a man — you do not do that," Cheng recalled. "And then two, I had never really articulated and said out loud those words. I hadn't even allowed myself to think that. But now they're out there and I had to face them.'
Colleagues responded by relaying their own struggles, but Cheng's difficulties continued. By February 2021, he couldn't get out of bed because he felt paralyzed by dread, he said. A therapist said he was showing symptoms of major depression and anxiety.
'I just realized, 'I'm struggling a lot and this goes pretty deep. I don't think I can keep just putting duct tape on this. I probably need to take some leave,'' Cheng recalled.
Hoping his decision would benefit others, he announced to 200 people at a conference that he planned to take mental health leave. Instead of derailing the gathering as he feared, his honesty inspired fellow conference attendees to open up.
"It was like a fireworks show,' Cheng said. 'They're like, 'Wow, I can't believe he did that.' Then they forgot about me. But the tone was set. It was like 'Oh, this is what we're doing. Let me talk about what's going on with me, too.''
Take the time you need
While balancing classes and a full-time job during her last year of college, Rosalie Mae began struggling to get out of bed and crying uncontrollably. Yet she felt like she had 'to keep it together' to avoid burdening her colleagues at the University of Utah bookstore, where Mae worked as an accounting clerk.
Then she found herself calling a suicide hotline. 'Once it reached that point, I knew, especially at the urging of my husband, we need to do something more,' Mae, 24, said.
In her case, that meant taking a five-week work leave to put her own health and well-being first. She recommends the same for others who find themselves in a similar position.
'Taking a mental health leave is not necessarily a cure-all, but it is important to give yourself a break and allow yourself to regroup, make a plan of how to proceed and take the steps to work towards feeling better," Mae said.
Telling managers and colleagues
Before broaching the subject of a mental health leave with a manager, consider the workplace culture and the strength of your professional relationships, Cheng said. He recalls saying, 'For my health and well-being, and the sake of my family and what's best for the business, the least risky thing for me to do is to go on leave soon.'
Individuals who suspect an unsympathetic reception can simply say, 'I need to go on medical leave. I need time to recover,' he advised.
There's also no legal or ethical requirement to tell everyone you work with the nature of your leave.
'Your coworkers don't need to know why,' said Seth Turner, co-founder of AbsenceSoft, a leave and accommodation management solutions provider. 'They just need to know, 'I'm going to be here at this time, and I'm going to be gone at this time, and I'll be back.''
___
Have you overcome an obstacle or made a profound change in your work? Send your questions and story ideas to cbussewitz@ap.org. Follow AP's Be Well coverage, focusing on wellness, fitness, diet and mental health at https://apnews.com/hub/be-well.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Post
23 minutes ago
- New York Post
Most people are guilty of doing this in the shower — but experts warn it's incredibly dangerous: ‘Don't do it'
What you do in the shower is your business, but the one thing experts are warning you to stop doing while sudsing up: peeing. One healthcare expert shared in a now-viral TikTok with over 1 million views that emptying your bladder while standing in the shower can be damaging — especially for women. Advertisement 'Hot take but don't pee standing up in the shower or anywhere for that matter. Ladies, you are training your bladder that it's okay to empty while standing. Don't do it! This could cause bladder leakage,' @kingsley.502 wrote as her caption. As expected, people ran to the comment section to share their opinions on this advice. 'My body created a human… I'm gonna let her tinkle wherever she likes,' one commenter wrote. Advertisement 'I can't even enjoy the simple pleasures in life,' shared another frustrated person. 'Meanwhile sitting for too long messes with our pelvic floor. So what actually is ok anymore?' said someone else, making a valid point. Many people in the comments of the viral TikTok video were upset to learn of this news. uduhunt – It's no surprise that this news is upsetting for many, considering almost a quarter of Americans admit to peeing in the shower regularly, according to a survey. Advertisement Unfortunately for these multitasking people, @kingsley.502 wasn't far off with her opinion on shower peeing — as other experts backed up her claims. 'It is one, not very hygienic, but more important than that, it will destroy your pelvic floor, and also it might create mental associations where you hear water running and all of a sudden you need to run to the bathroom,' Houston-based OB-GYN Emma Qureshey explained in a TikTok. And standing while peeing is not only unhealthy for women — it's also dangerous for men. Advertisement Since the pelvis and spine muscles are most relaxed when sitting, Gerald Collins, a consultant urological surgeon at Alexandra Hospital in Cheshire, England, said that 'Sitting is probably the most efficient way of doing it [peeing]' the doctor explained, Standing while urinating also puts men at risk for benign prostatic hyperplasia — which occurs when the prostate gland and surrounding tissue expand, obstructing the urethra. Sadly, for many men, the thought of sitting while peeing is looked down upon. In Germany, those who don't stand to relieve themselves are called 'Sitzpinkler' — a slur implying they are 'wimpy or effeminate.'


Business Upturn
30 minutes ago
- Business Upturn
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development Plans Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Brittany ChavesSenior Manager, Investor Relations [email protected]


Axios
2 hours ago
- Axios
Exclusive: Zorro clinches $20M Series A for ICHRA health plans
Health benefits provider Zorro raised $20 million in Series A funding led by Entrée Capital, CEO Guy Ezekiel tells Axios exclusively. Why it matters: As employers wrestle with rising health plan costs, individual coverage health reimbursement arrangements (ICHRAs) are gaining steam. Driving the news: Launched in 2020, ICHRAs were enabled by a Trump-era rule letting employers reimburse employees tax-free for individual health insurance instead of offering group plans. After a slow start, rule clarifications and compliance tools made them more accessible to midsized employers. Follow the money: Existing backers Pitango and 10D joined the round, which will be used to scale operations and improve support for employers. The Series A brings Zorro to $31.5 million total raised. The company is not yet profitable. How it works: New York City-based Zorro replaces traditional group plans with defined-contribution models. Employers set a budget; employees use Zorro's AI engine to select personalized plans, and brokers get real-time tools to compare group plans versus ICHRA-based options. When it onboards an employer, Zorro asks them to send their benefits roster from the previous year, asks about quality and budget priorities for the upcoming year, and helps predict what benefits employees might want next. Zorro has "several thousand" lives on the platform, per Ezekiel. Between the lines: Zorro's pitch hinges not just on cost control but on its ability to shift complex decision-making from HR to software — claiming that 75% of users enroll without human help. What they're saying: "We're giving the employer a line of sight to how his upcoming year is going to look," says Ezekiel. Reality check: While ICHRAs are gaining traction, they remain a small fraction of the employer market. Zorro's long-term success depends on widespread broker adoption and employee trust in AI-led benefit decisions. State of play: A February Bailey's report predicted the debut of several new ICHRA startups in 2025. Several others have secured recent funding. In April, Thatch raised $40 million in Series B funding led by Index Ventures and Venteur Health Insurance raised a $20 million Series A led by Informed Ventures and American Family Ventures. Remodel Health last December collected more than $100 million in a round led by Oak HC/FT and Hercules Capital.